These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24059244)

  • 21. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
    Natrajan R; Weigelt B; Mackay A; Geyer FC; Grigoriadis A; Tan DS; Jones C; Lord CJ; Vatcheva R; Rodriguez-Pinilla SM; Palacios J; Ashworth A; Reis-Filho JS
    Breast Cancer Res Treat; 2010 Jun; 121(3):575-89. PubMed ID: 19688261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation.
    Bhattarai S; Sugita BM; Bortoletto SM; Fonseca AS; Cavalli LR; Aneja R
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
    Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
    Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of micrornas in molecular genetic breast cancer subtypes.
    Kolesnikov NN; Veryaskina YA; Titov SE; Rodionov VV; Gening TP; Abakumova TV; Kometova VV; Torosyan MK; Zhimulev IF
    Cancer Treat Res Commun; 2019; 20():100026. PubMed ID: 31255253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.
    Wang X; Guda C
    Medicine (Baltimore); 2016 Jul; 95(30):e4321. PubMed ID: 27472710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.
    Johnstone CN; Pattison AD; Gorringe KL; Harrison PF; Powell DR; Lock P; Baloyan D; Ernst M; Stewart AG; Beilharz TH; Anderson RL
    Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29720474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
    Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model-Based Integration Analysis Revealed Presence of Novel Prognostic miRNA Targets and Important Cancer Driver Genes in Triple-Negative Breast Cancers.
    Zaka M; Sutton CW; Peng Y; Konur S
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32182819
    [No Abstract]   [Full Text] [Related]  

  • 29. Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer.
    Chiu AM; Mitra M; Boymoushakian L; Coller HA
    Sci Rep; 2018 Aug; 8(1):11807. PubMed ID: 30087365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-506-loaded gelatin nanospheres target PENK and inactivate the ERK/Fos signaling pathway to suppress triple-negative breast cancer aggressiveness.
    Liu XL; Liu WJ; Chen Q; Liu J; Yang CQ; Zhang G; Zhang SL; Guo WH; Li JB; Zhao G; Yin DC; Zhang CY
    Mol Carcinog; 2021 Aug; 60(8):538-555. PubMed ID: 34062009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep Sequencing Reveals a MicroRNA Expression Signature in Triple-Negative Breast Cancer.
    Chang YY; Lai LC; Tsai MH; Chuang EY
    Methods Mol Biol; 2018; 1699():99-111. PubMed ID: 29086372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer.
    Johnson JP; Kumar P; Koulnis M; Patel M; Simin K
    Cancer Genomics Proteomics; 2014; 11(3):115-26. PubMed ID: 24969692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated Analysis of mRNA-miRNA-lncRNA ceRNA Network in Human HR+/Her-2- Breast Cancer and Triple Negative Breast Cancer.
    Jia X; Shi Y; Zhu Y; Meng W; He L; Jia Y; Tong Z
    J Comput Biol; 2020 Jul; 27(7):1055-1066. PubMed ID: 31647320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
    Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P
    Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
    Yang F; Zhang W; Shen Y; Guan X
    Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.